- Mylan (NASDAQ:MYL) won't be appearing at a November 30 Senate hearing about the EpiPen, stating its $465M settlement with the Justice Department is a "pending matter" and the DOJ will also not be attending.
- At issue is whether Mylan underpaid government healthcare plans by classifying the Epipen as generic in the Medicaid Drug Rebate Program.